Yurong Lai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2157652/publications.pdf

Version: 2024-02-01

153 papers	6,939 citations	38660 50 h-index	66788 78 g-index
161 all docs	161 docs citations	161 times ranked	5063 citing authors

#	Article	IF	Citations
1	Kidney transporters drug discovery, development, and safety. Current Opinion in Toxicology, 2022, 29, 65-69.	2.6	0
2	Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Acta Pharmaceutica Sinica B, 2022, 12, 2751-2777.	5.7	27
3	Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions. Clinical Pharmacology and Therapeutics, 2022, 111, 1315-1323.	2.3	16
4	Physiologicallyâ€based pharmacokinetic modelâ€based translation of <scp>OATP1B</scp>â€mediated drugâ€“drug interactions from coproporphyrin I to probe drugs. Clinical and Translational Science, 2022, 15, 1519-1531.	1.5	13
5	Transporters and Toxicity: Insights From the International Transporter Consortium Workshop 4. Clinical Pharmacology and Therapeutics, 2022, 112, 527-539.	2.3	4
6	Intestinal Pâ€glycoprotein (Pâ€gp) Contribution to Talinolol Pharmacokinetics in Human. FASEB Journal, 2022, 36, .	0.2	0
7	Quantitative Expression of Drug, Phospholipid and Nucleoside Transporters in the Lung Tissues across Species. FASEB Journal, 2022, 36, .	0.2	0
8	Clinical Relevance of Hepatic and Renal Pâ€gp/<scp>BCRP</scp> Inhibition of Drugs: An International Transporter Consortium Perspective. Clinical Pharmacology and Therapeutics, 2022, 112, 573-592.	2.3	15
9	Special Section on Pharmacokinetics and ADME of Biological Therapeuticsâ€“Editorial. Drug Metabolism and Disposition, 2022, 50, 819-821.	1.7	0
10	Intestinal Pâ€gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications. Clinical Pharmacology and Therapeutics, 2021, 109, 55-64.	2.3	38
11	Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach. Drug Metabolism and Disposition, 2021, 49, 159-168.	1.7	24
12	Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs. Journal of Medicinal Chemistry, 2021, 64, 7045-7059.	2.9	9
13	Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys. Clinical and Translational Science, 2021, 14, 1924-1934.	1.5	5
14	Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 869-886.	1.5	9
15	Endogenous Plasma Kynurenic Acid in Human: A Newly Discovered Biomarker for Drug-Drug Interactions Involving Organic Anion Transporter 1 and 3 Inhibition. Drug Metabolism and Disposition, 2021, 49, 1063-1069.	1.7	8
16	Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?. Drug Metabolism and Disposition, 2020, 48, 205-216.	1.7	36
17	In Vitro Hepatic Uptake in Human and Monkey Hepatocytes in the Presence and Absence of Serum Protein and Its In Vitro to In Vivo Extrapolation. Drug Metabolism and Disposition, 2020, 48, 1283-1292.	1.7	16
18	P79 - Effects of the Pregnane X Receptor (PXR) activator rifampin on transporter gene expressions: Studies in hepatocytes in vitro and in monkeys in in vivo. Drug Metabolism and Pharmacokinetics, 2020, 35, S46.	1.1	0

#	Article	IF	Citations
19	P129 - In-vivo transporter-mediated hepatic clearance of rosuvastatin in humans could be better predicted using transporter-expressing cells than hepatocytes. Drug Metabolism and Pharmacokinetics, 2020, 35, S61-S62.	1.1	0
20	Role of transporters in drug disposition and drug-drug interactions. , 2020, , 311-337.		3
21	Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. Drug Metabolism and Disposition, 2020, 48, 724-734.	1.7	7
22	Transporter Gene Regulation in Sandwich Cultured Human Hepatocytes Through the Activation of Constitutive Androstane Receptor (CAR) or Aryl Hydrocarbon Receptor (AhR). Frontiers in Pharmacology, 2020, 11, 620197.	1.6	7
23	Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells. Frontiers in Pharmacology, 2019, 10, 749.	1.6	30
24	Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo. Drug Metabolism and Disposition, 2019, 47, 1433-1442.	1.7	19
25	Interindividual and Regional Variability in Drug Transporter Abundance at the Human Bloodâ€“Brain Barrier Measured by Quantitative Targeted Proteomics. Clinical Pharmacology and Therapeutics, 2019, 106, 228-237.	2.3	64
26	Toward a Consensus on Applying Quantitative Liquid Chromatographyâ€Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper. Clinical Pharmacology and Therapeutics, 2019, 106, 525-543.	2.3	77
27	Positron Emission Tomography Imaging of [¹¹C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A. Clinical Pharmacology and Therapeutics, 2019, 106, 1056-1066.	2.3	51
28	Does plasma membrane and total transporter abundance differ between suspended, plated, sandwich culture hepatocytes and human liver tissue?. Drug Metabolism and Pharmacokinetics, 2019, 34, S17.	1.1	0
29	Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drugâ€“Drug Interaction and Associated Biomarker Levels in Healthy Volunteers. Clinical and Translational Science, 2019, 12, 388-399.	1.5	53
30	Drug Concentration Asymmetry in Tissues and Plasma for Small Moleculeâ€“Related Therapeutic Modalities. Drug Metabolism and Disposition, 2019, 47, 1122-1135.	1.7	79
31	A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation. Drug Metabolism and Disposition, 2019, 47, 350-357.	1.7	37
32	Characterization of Hepatocytes Uptake Clearance of Organic Anion Transporting Polypeptide (OATPs) Substrates in Human and Cynomolgus Cryopreserved Hepatocytes. FASEB Journal, 2019, 33, .	0.2	0
33	Endogenous probes for transporter-mediated drugâ€“drug interaction. Drug Metabolism and Pharmacokinetics, 2018, 33, S7.	1.1	0
34	Drug Transporters in Xenobiotic Disposition and Pharmacokinetic Prediction. Drug Metabolism and Disposition, 2018, 46, 561-566.	1.7	30
35	Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. Drug Metabolism and Disposition, 2018, 46, 189-196.	1.7	43
36	Transporter expression in non-cancerous and cancerous liver tissue from subjects with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS/MS proteomics. Drug Metabolism and Pharmacokinetics, 2018, 33, S18-S19.	1.1	0

#	Article	IF	Citations
37	Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys. Drug Metabolism and Disposition, 2018, 46, 178-188.	1.7	40
38	Comparative untargeted proteomic analysis of ADME proteins and tumor antigens for tumor cell lines. Acta Pharmaceutica Sinica B, 2018, 8, 252-260.	5.7	5
39	Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. Drug Metabolism and Disposition, 2018, 46, 943-952.	1.7	74
40	Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1Bâ€Mediated Drugâ€“Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. Clinical Pharmacology and Therapeutics, 2018, 104, 564-574.	2.3	56
41	In Vitro Stimulation of Multidrug Resistance-Associated Protein 2 Function Is Not Reproduced In Vivo in Rats. Pharmaceutics, 2018, 10, 125.	2.0	5
42	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drugâ€Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2018, 104, 836-864.	2.3	141
43	Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition. Drug Metabolism and Disposition, 2018, 46, 1075-1082.	1.7	44
44	UHPLCâ€“MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions. Bioanalysis, 2018, 10, 633-644.	0.6	14
45	Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective. Clinical Pharmacology and Therapeutics, 2018, 104, 916-932.	2.3	80
46	Transporter Roles in the Pharmacokinetics and Tissue Distribution of Voxilaprevir, a Panâ€genotypic HCV NS3/4A Protease Inhibitor. FASEB Journal, 2018, 32, 828.5.	0.2	0
47	Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 341-342.	1.3	6
48	Organic Anion Transporter 2: An Enigmatic Human Solute Carrier. Drug Metabolism and Disposition, 2017, 45, 228-236.	1.7	62
49	Molecular properties associated with transporter-mediated drug disposition. Advanced Drug Delivery Reviews, 2017, 116, 92-99.	6.6	22
50	Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay. Drug Metabolism and Disposition, 2017, 45, 604-611.	1.7	48
51	Disrupted Murine Gutâ€“toâ€“Human Liver Signaling Alters Bile Acid Homeostasis in Humanized Mouse Liver Models. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 174-191.	1.3	23
52	Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. AAPS Journal, 2017, 19, 1878-1889.	2.2	13
53	Bile Salt Homeostasis in Normal and Bsep Gene Knockout Rats with Single and Repeated Doses of Troglitazone. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 385-394.	1.3	9
54	Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects. Drug Metabolism and Disposition, 2017, 45, 908-919.	1.7	67

#	Article	IF	Citations
55	Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach. Drug Metabolism and Disposition, 2016, 44, 505-516.	1.7	43
56	The Importance of In Vitro Liver Models: Experts Discuss Whole-Cell Systems, Transporter Function, and the Best Models for Future In Vitro Testing. Applied in Vitro Toxicology, 2016, 2, 1-7.	0.6	4
57	Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 382-393.	1.3	88
58	Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics. Drug Metabolism and Disposition, 2016, 44, 1752-1758.	1.7	100
59	Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 397-404.	1.3	132
60	Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation. Drug Metabolism and Disposition, 2016, 44, 238-249.	1.7	28
61	Biliary excretion of pravastatin and taurocholate in rats with bile salt export pump (Bsep) impairment. Biopharmaceutics and Drug Disposition, 2016, 37, 276-286.	1.1	16
62	Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development. Chemical Research in Toxicology, 2016, 29, 545-563.	1.7	18
63	Disruption of BSEP Function in HepaRG Cells Alters Bile Acid Disposition and Is a Susceptive Factor to Drug-Induced Cholestatic Injury. Molecular Pharmaceutics, 2016, 13, 1206-1216.	2.3	38
64	Diclofenac and Its Acyl Glucuronide: Determination of In Vivo Exposure in Human Subjects and Characterization as Human Drug Transporter Substrates In Vitro. Drug Metabolism and Disposition, 2016, 44, 320-328.	1.7	55
65	Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression. Drug Metabolism and Disposition, 2015, 43, 984-993.	1.7	73
66	Evaluation of Rosuvastatin as an Organic Anion Transporting Polypeptide (OATP) Probe Substrate: In Vitro Transport and In Vivo Disposition in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 380-391.	1.3	31
67	Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-Î²-Glucuronide. Molecular Pharmaceutics, 2015, 12, 3943-3952.	2.3	33
68	Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake. Drug Metabolism and Disposition, 2015, 43, 1788-1794.	1.7	21
69	Hepatic Uptake of Atorvastatin: Influence of Variability in Transporter Expression on Uptake Clearance and Drug-Drug Interactions<sup />. Drug Metabolism and Disposition, 2014, 42, 1210-1218.	1.7	98
70	Drug-Induced Perturbations of the Bile Acid Pool, Cholestasis, and Hepatotoxicity: Mechanistic Considerations beyond the Direct Inhibition of the Bile Salt Export Pump. Drug Metabolism and Disposition, 2014, 42, 566-574.	1.7	90
71	Protein Abundance of Clinically Relevant Multidrug Transporters along the Entire Length of the Human Intestine. Molecular Pharmaceutics, 2014, 11, 3547-3555.	2.3	211
72	Permeability Comparison between Hepatocyte and Low Efflux MDCKII Cell Monolayer. AAPS Journal, 2014, 16, 802-809.	2.2	22

#	Article	IF	Citations
73	Quantitative Targeted Proteomics for Membrane Transporter Proteins: Method and Application. AAPS Journal, 2014, 16, 714-726.	2.2	18
74	Beyond the ITC White Paper: Emerging Sciences in Drug Transporters and Opportunities for Drug Development. Current Pharmaceutical Design, 2014, 20, 1577-1594.	0.9	15
75	Response to the Comment on the Article â€œPhysiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactionsâ€• Pharmaceutical Research, 2013, 30, 1469-1470.	1.7	3
76	Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide. Pharmaceutical Research, 2013, 30, 1188-1199.	1.7	96
77	In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development. Clinical Pharmacology and Therapeutics, 2013, 94, 95-112.	2.3	224
78	Absolute measurement of species differences in sodium taurocholate cotransporting polypeptide (NTCP/Ntcp) and its modulation in cultured hepatocytes. Journal of Pharmaceutical Sciences, 2013, 102, 3252-3263.	1.6	42
79	LCâ€“MS/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins. Journal of Pharmaceutical and Biomedical Analysis, 2013, 85, 253-261.	1.4	135
80	A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development. Drug Metabolism and Disposition, 2013, 41, 1975-1993.	1.7	89
81	Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma. Hepatology, 2013, 57, 1530-1541.	3.6	67
82	Organic anion, organic cation and zwitterion transporters of the SLC22 and SLC47 superfamily (OATs,) Tj ETQq0 0 0 rgBT /Overlock 10 T		1
83	The bile salt export pump (BSEP/ABCB11). , 2013, , 327-352.		2
84	Drug transporters in drug discovery and development. , 2013, , 633-674.		3
85	Model-based approaches to predict drugâ€“drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 459-472.	1.5	63
86	Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver. Clinical Pharmacology and Therapeutics, 2013, 94, 126-141.	2.3	228
87	Organic anion-transporting polypeptides (OATPs/SLCOs). , 2013, , 353-454.		0
88	Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin. Drug Metabolism and Disposition, 2013, 41, 966-974.	1.7	55
89	Multidrug resistance-associated protein 2 (MRP2/ABCC2). , 2013, , 261-294.		1
90	Breast cancer resistance protein (BCRP)/ABCG2. , 2013, , 295-326.		1

#	Article	IF	Citations
91	Transporter study methodologies. , 2013, , 675-718.		2
92	Inhibition of Hepatobiliary Transporters by A Novel Kinase Inhibitor Contributes to Hepatotoxicity in Beagle Dogs. Drug Metabolism Letters, 2013, 7, 15-22.	0.5	8
93	Quantitative assessment of the contribution of sodiumâ€dependent taurocholate coâ€transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Biopharmaceutics and Drug Disposition, 2013, 34, 452-461.	1.1	72
94	Interindividual Variability in the Hepatic Expression of the Human Breast Cancer Resistance Protein (BCRP/ABCG2): Effect of Age, Sex, and Genotype. Journal of Pharmaceutical Sciences, 2013, 102, 787-793.	1.6	99
95	P-glycoprotein (P-gp/MDR1)/ABCB1. , 2013, , 147-259.		4
96	Applications of Targeted Proteomics in ADME for IVIVE. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 99-119.	0.2	1
97	Membrane Protein Quantification by Peptide-Based Mass Spectrometry Approaches: Studies on the Organic Anion-Transporting Polypeptide Family. Journal of Proteomics and Bioinformatics, 2013, 06, .	0.4	12
98	Predicting plasma profiles following oral dosing for drug liver transporter substrates using physiologically based pharmacokinetic modeling. FASEB Journal, 2013, 27, lb624.	0.2	0
99	The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica, 2012, 42, 28-45.	0.5	51
100	Differential Modulation of Cytochrome P450 Activity and the Effect of 1-Aminobenzotriazole on Hepatic Transport in Sandwich-Cultured Human Hepatocytes. Drug Metabolism and Disposition, 2012, 40, 407-411.	1.7	33
101	Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data. Drug Metabolism and Disposition, 2012, 40, 1007-1017.	1.7	228
102	Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion. Drug Metabolism and Disposition, 2012, 40, 1527-1537.	1.7	66
103	In Vitro Evaluation of Hepatic Transporter-Mediated Clinical Drug-Drug Interactions: Hepatocyte Model Optimization and Retrospective Investigation. Drug Metabolism and Disposition, 2012, 40, 1085-1092.	1.7	58
104	Interindividual Variability in Hepatic Expression of the Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2): Quantification by Liquid Chromatography/Tandem Mass Spectrometry. Drug Metabolism and Disposition, 2012, 40, 852-855.	1.7	79
105	A Novel Relay Method for Determining Low-Clearance Values. Drug Metabolism and Disposition, 2012, 40, 1860-1865.	1.7	94
106	Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. European Journal of Medicinal Chemistry, 2012, 57, 441-448.	2.6	119
107	Characterization of Organic Anion Transporting Polypeptide (OATP) Expression and Its Functional Contribution to the Uptake of Substrates in Human Hepatocytes. Molecular Pharmaceutics, 2012, 9, 3535-3542.	2.3	94
108	Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions. Pharmaceutical Research, 2012, 29, 2860-2873.	1.7	122

#	Article	IF	Citations
109	Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability â€“ considerations for drug development. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 723-743.	1.5	49
110	Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drugâ€“Drug Interactions. Journal of Medicinal Chemistry, 2012, 55, 4740-4763.	2.9	299
111	Quantitative Membrane Proteomics and its Application in Translational Pharmacology. Journal of Proteomics and Bioinformatics, 2012, 05, .	0.4	0
112	Pharmacokinetic Interaction of the Antiparasitic Agents Ivermectin and Spinosad in Dogs. Drug Metabolism and Disposition, 2011, 39, 789-795.	1.7	43
113	Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of Pâ€glycoprotein in various biological samples. Rapid Communications in Mass Spectrometry, 2011, 25, 1715-1724.	0.7	39
114	Development of a new permeability assay using lowâ€efflux MDCKII cells. Journal of Pharmaceutical Sciences, 2011, 100, 4974-4985.	1.6	254
115	Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2725-2731.	1.0	27
116	Evaluation of Drug Transporter Interactions in Drug Discovery and Development. Combinatorial Chemistry and High Throughput Screening, 2010, 13, 112-134.	0.6	20
117	Preclinical and Clinical Evidence for the Collaborative Transport and Renal Secretion of an Oxazolidinone Antibiotic by Organic Anion Transporter 3 (OAT3/SLC22A8) and Multidrug and Toxin Extrusion Protein 1 (MATE1/SLC47A1). Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 936-944.	1.3	30
118	Novel Metabolic Bioactivation Mechanism for a Series of Anti-Inflammatory Agents (2,5-Diaminothiophene Derivatives) Mediated by Cytochrome P450 Enzymes. Drug Metabolism and Disposition, 2010, 38, 1522-1531.	1.7	14
119	Regulation of MRP2/ABCC2 and BSEP/ABCB11 Expression in Sandwich Cultured Human and Rat Hepatocytes Exposed to Inflammatory Cytokines TNF-Î±, IL-6, and IL-1Î². Journal of Biological Chemistry, 2010, 285, 31185-31192.	1.6	61
120	Two Branched Polar Groups and Polar Linker Moieties of Thiophene Amide Derivatives Are Essential for MRP2/ABCC2 Recognition. Drug Metabolism Letters, 2010, 4, 254-261.	0.5	2
121	Improved Extrapolation of Hepatobiliary Clearance from in Vitro Sandwich Cultured Rat Hepatocytes through Absolute Quantification of Hepatobiliary Transporters. Molecular Pharmaceutics, 2010, 7, 630-641.	2.3	68
122	Evaluation of in Vitro Models for Screening Alkaline Phosphatase-Mediated Bioconversion of Phosphate Ester Prodrugs. Drug Metabolism and Disposition, 2009, 37, 1443-1447.	1.7	37
123	Absolute Difference of Hepatobiliary Transporter Multidrug Resistance-Associated Protein (MRP2/Mrp2) in Liver Tissues and Isolated Hepatocytes from Rat, Dog, Monkey, and Human. Drug Metabolism and Disposition, 2009, 37, 66-73.	1.7	88
124	Saturation of Multidrug-Resistant Protein 2 (Mrp2/Abcc2)-Mediated Hepatobiliary Secretion: Nonlinear Pharmacokinetics of a Heterocyclic Compound in Rats after Intravenous Bolus Administration. Drug Metabolism and Disposition, 2009, 37, 841-846.	1.7	12
125	Pharmacokinetic and Pharmacodynamic Evaluation of the Suitability of Using Fluticasone and an Acute Rat Lung Inflammation Model to Differentiate Lung Versus Systemic Efficacy. Journal of Pharmaceutical Sciences, 2009, 98, 4354-4364.	1.6	9
126	Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery. Nanoscale Research Letters, 2009, 4, 254-261.	3.1	45

#	Article	IF	Citations
127	Advancement of Structure-Activity Relationship of Multidrug Resistance-Associated Protein 2 Interactions. AAPS Journal, 2009, 11, 406-13.	2.2	13
128	Quantitative Expression Profile of Hepatobiliary Transporters in Sandwich Cultured Rat and Human Hepatocytes. Molecular Pharmaceutics, 2009, 6, 1180-1189.	2.3	71
129	LCâ^'MS/MS Mediated Absolute Quantification and Comparison of Bile Salt Export Pump and Breast Cancer Resistance Protein in Livers and Hepatocytes across Species. Analytical Chemistry, 2009, 81, 2251-2259.	3.2	95
130	Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1175-1187.	1.5	52
131	Comparison of InÂvitro Nanoparticles Uptake in Various Cell Lines and InÂvivo Pulmonary Cellular Transport in Intratracheally Dosed Rat Model. Nanoscale Research Letters, 2008, 3, 321-329.	3.1	36
132	Absolute quantification of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry. Analytical Biochemistry, 2008, 380, 211-222.	1.1	62
133	Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. European Journal of Pharmaceutical Sciences, 2008, 35, 114-126.	1.9	105
134	In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R1809-R1822.	0.9	126
135	Structure-Activity Relationships for Interaction with Multidrug Resistance Protein 2 (ABCC2/MRP2): The Role of Torsion Angle for a Series of Biphenyl-Substituted Heterocycles. Drug Metabolism and Disposition, 2007, 35, 937-945.	1.7	34
136	Enhanced production of p24 Gag protein in HIV-1-infected rat cells fused with uninfected human cells. Experimental and Molecular Pathology, 2007, 83, 125-130.	0.9	2
137	Changes in Pharmacokinetics of Anti-HIV Protease Inhibitors during Pregnancy: The Role of CYP3A and P-glycoprotein. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1202-1209.	1.3	29
138	Identification of the Mitochondrial Targeting Signal of the Human Equilibrative Nucleoside Transporter 1 (hENT1). Journal of Biological Chemistry, 2006, 281, 16700-16706.	1.6	95
139	Conserved residues F316 and G476 in the concentrative nucleoside transporter 1 (hCNT1) affect guanosine sensitivity and membrane expression, respectively. American Journal of Physiology - Cell Physiology, 2005, 288, C39-C45.	2.1	20
140	Improving branch prediction accuracy with parallel conservative correctors. , 2005, , .		1
141	Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs. Journal of Biological Chemistry, 2004, 279, 4490-4497.	1.6	123
142	Epstein-barr virus infection of rat lymphocytes expressing human CD21 results in restricted latent viral gene expression and not in immunoblastic transformation. Journal of Medical Virology, 2003, 70, 126-130.	2.5	6
143	Simultaneous Expression of hCNT1-CFP and hENT1-YFP in Madin-Darby Canine Kidney Cells. Journal of Biological Chemistry, 2002, 277, 37711-37717.	1.6	71
144	A Single Glycine Mutation in the Equilibrative Nucleoside Transporter Gene, hENT1, Alters Nucleoside Transport Activity and Sensitivity to Nitrobenzylthioinosine. Biochemistry, 2002, 41, 1512-1519.	1.2	79

#	Article	IF	Citations
145	Iron depletion prevents adenine nucleotide decomposition and an increase of xanthine oxidase activity in the liver of the Long Evans Cinnamon (LEC) rat, an animal model of Wilson's disease. Life Sciences, 1999, 65, 1423-1431.	2.0	18
146	Decreased hepatobiliary secretion of inorganic mercury, its deposition and toxicity in the Eisai hyperbilirubinemic rat with no hepatic canalicular organic anion transporter. Toxicology, 1998, 126, 23-31.	2.0	30
147	Lack of biliary excretion of Cd linked to an inherent defect of the canalicular isoform of multidrug resistance protein (cMrp) does not abnormally stimulate accumulation of Cd in the Eisai hyperbilirubinemic (EHB) rat liver. Archives of Toxicology, 1997, 71, 336-339.	1.9	11
148	Outputs of hepatic copper and cadmium stimulated by tetrathiomolybdate (TTM) injection in Long-Evans Cinnamon (LEC) rats pretreated with cadmium, and in Fischer rats pretreated with copper and cadmium. Toxicology, 1997, 120, 47-54.	2.0	7
149	Biliary excretion of copper, manganese, and horseradish peroxidase in eisai hyperbilirubinemic mutant rats (EHBRs) with defective biliary excretion of glutathione. Biological Trace Element Research, 1996, 55, 181-189.	1.9	5
150	Accumulation of orally given cadmium in Long-Evans Cinnamon (LEC) rats with an inherently abnormal copper metabolism. Toxicology, 1996, 108, 1-7.	2.0	8
151	Biliary excretion of exogenous cadmium, and endogenous copper and zinc in the Eisai hyperbilirubinuric (EHB) rat with a near absence of biliary glutathione. Toxicology, 1996, 112, 87-94.	2.0	17
152	The protective role of zinc in the toxic action of coal dust upon mouse macrophages.. Occupational and Environmental Medicine, 1991, 48, 838-840.	1.3	0
153	Influence of rheumatoid factor in coalminers' pneumoconiosis in the Fujian Shaowu colliery, south China.. Occupational and Environmental Medicine, 1990, 47, 143-144.	1.3	3